|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang X, Yin H, Zhang L, Zheng D, Yang Y,
Zhang J, Jiang H, Ling X, Xin Y, Liang H, et al: The construction
and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small
cell lung cancer. J Thorac Dis. 11:1772–1778. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qiu M, Chen YB, Jin S, Fang XF, He XX,
Xiong ZF and Yang SL: Research on circadian clock genes in
non-small-cell lung carcinoma. Chronobiol Int. 36:739–750. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu XJ, Chen G, Yang J, Yu GC, Zhu PF,
Jiang ZK, Feng K, Lu Y, Bao B and Zhong FM: Smoking alters the
evolutionary trajectory of non-small cell lung cancer. Exp Ther
Med. 18:3315–3324. 2019.PubMed/NCBI
|
|
5
|
Nigro E, Imperlini E, Scudiero O, Monaco
ML, Polito R, Mazzarella G, Orrù S, Bianco A and Daniele A:
Differentially expressed and activated proteins associated with non
small cell lung cancer tissues. Respir Res. 16:742015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Braicu C, Zimta AA, Harangus A, Iurca I,
Irimie A, Coza O and Berindan-Neagoe I: The function of non-coding
RNAs in lung cancer tumorigenesis. Cancers (Basel). 11:6052019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Narsule CK, Sridhar P, Nair D, Gupta A,
Oommen RG, Ebright MI, Litle VR and Fernando HC: Percutaneous
thermal ablation for stage IA non-small cell lung cancer: Long-term
follow-up. J Thorac Dis. 9:4039–4045. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Shen WX, Zhou LN, Tang M, Tan Y,
Feng CX, Li P, Wang LQ and Chen MB: The value of next-generation
sequencing for treatment in non-small cell lung cancer patients:
The observational, real-world evidence in China. Biomed Res Int.
2020:93871672020.PubMed/NCBI
|
|
9
|
Yeh J, Marrone KA and Forde PM:
Neoadjuvant and consolidation immuno-oncology therapy in stage III
non-small cell lung cancer. J Thorac Dis. 10 (Suppl 3):S451–S459.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan WL, Jain A, Takano A, Newell EW, Iyer
NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL and Tan DSW: Novel
therapeutic targets on the horizon for lung cancer. Lancet Oncol.
17:e347–e362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith RA, Andrews KS, Brooks D, Fedewa SA,
Manassaram-Baptiste D, Saslow D, Brawley OW and Wender RC: Cancer
screening in the United States, 2017: A review of current American
Cancer Society guidelines and current issues in cancer screening.
CA Cancer J Clin. 67:100–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dagogo-Jack I and Shaw AT: Crizotinib
resistance: Implications for therapeutic strategies. Ann Oncol. 27
(Suppl 3):iii42–iii50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baird DM: Variation at the TERT locus and
predisposition for cancer. Expert Rev Mol Med. 12:e162010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meena J, Rudolph KL and Gunes C: Telomere
dysfunction, chromosomal instability and cancer. Recent Results
Cancer Res. 200:61–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng D, Zhao Y, Zhang F, Zhang J, Wang S
and Zhu J: Engineering a humanized telomerase reverse transcriptase
gene in mouse embryonic stem cells. Sci Rep. 9:96832019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inada E, Saitoh I, Kubota N, Iwase Y,
Kiyokawa Y, Shibasaki S, Noguchi H, Yamasaki Y and Sato M: piggyBac
transposon-based immortalization of human deciduous tooth dental
pulp cells with multipotency and non-tumorigenic potential. Int J
Mol Sci. 20:49042019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muneer A and Minhas FA: Telomere biology
in mood disorders: An updated, comprehensive review of the
literature. Clin Psychopharmacol Neurosci. 17:343–363. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campisi J: Aging, cellular senescence, and
cancer. Annu Rev Physiol. 75:685–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng J, Funk WD, Wang SS, Weinrich SL,
Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, et al:
The RNA component of human telomerase. Science. 269:1236–1241.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakamura TM, Morin GB, Chapman KB,
Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR:
Telomerase catalytic subunit homologs from fission yeast and human.
Science. 277:955–959. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsang JYS, Hui YK, Lee MA, Lacambra M, Ni
YB, Cheung SY, Wu C, Kwong A and Tse GMK: Association of
clinicopathological features and prognosis of TERT alterations in
phyllodes tumor of breast. Sci Rep. 8:38812018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mortazavi-Haghighat R, Taghipour-Khiabani
K, David S, Kerrigan CL and Philip A: Rapid and dynamic regulation
of TGF-beta receptors on blood vessels and fibroblasts during
ischemia-reperfusion injury. Am J Physiol Cell Physiol.
282:C1161–C1169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Pedro N, Díez M, García I, García J,
Otero L, Fernandez L, Garcia B, González R, Rincón S, Pérez D, et
al: Analytical validation of telomere analysis
technology® for the High-throughput analysis of multiple
telomere-associated variables. Biol Proced Online. 22:22020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barthel FP, Wei W, Tang M,
Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang
Q, et al: Systematic analysis of telomere length and somatic
alterations in 31 cancer types. Nat Genet. 49:349–357. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung SJ, Kim DS, Park WJ, Lee H, Choi IJ,
Park JY and Lee JH: Mutation of the TERT promoter leads to poor
prognosis of patients with non-small cell lung cancer. Oncol Lett.
14:1609–1614. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leão R, Apolónio JD, Lee D, Figueiredo A,
Tabori U and Castelo-Branco P: Mechanisms of human telomerase
reverse transcriptase (hTERT) regulation: Clinical impacts in
cancer. J Biomed Sci. 25:222018. View Article : Google Scholar
|
|
28
|
da Silva EM, Selenica P, Vahdatinia M,
Pareja F, Da Cruz Paula A, Ferrando L, Gazzo AM, Dopeso H, Ross DS,
Bakhteri A, et al: TERT promoter hotspot mutations and gene
amplification in metaplastic breast cancer. NPJ Breast Cancer.
7:432021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen W, Xiong X, Zhou H and Zhou Q:
Expression of telomerase activity, telomerase RNA component and
telomerase catalytic subunit gene in lung cancer. Chin Med J
(Engl). 115:290–292. 2002.PubMed/NCBI
|
|
30
|
Dobija-Kubica K, Zalewska-Ziob M,
Brulinski K, Rogozinski P, Wiczkowski A, Gawrychowska A and
Gawrychowski J: Telomerase activity in non-small cell lung cancer.
Kardiochir Torakochirurgia Pol. 13:15–20. 2016.PubMed/NCBI
|
|
31
|
Liu H, Zhang W, Cai C, Xu J and Xu Y:
Telomerase activity in human non-small cell lung cancer (NSCLC).
Zhonghua Bing Li Xue Za Zhi. 29:89–91. 2000.(In Chinese).
PubMed/NCBI
|
|
32
|
Yang HZ, Hu CP and Su XL: Detection of
telomerase activity level in human non-small-cell lung cancer.
Hunan Yi Ke Da Xue Xue Bao. 26:549–550. 2001.(In Chinese).
PubMed/NCBI
|
|
33
|
Chen Q, He J and Yi H: Study on telomerase
activity and its clinical value in human non small cell lung
cancer. Hunan Yi Ke Da Xue Xue Bao. 26:221–222. 2001.(In Chinese).
PubMed/NCBI
|
|
34
|
Wang J, Liu X, Jiang W and Liang L:
Telomerase activity and expression of the telomerase catalytic
subunit gene in non-small cell lung cancer: Correlation with
decreased apoptosis and clinical prognosis. Chin Med J (Engl).
113:985–990. 2000.PubMed/NCBI
|
|
35
|
Fernandez-Marcelo T, Gomez A, Pascua I, de
Juan C, Head J, Hernando F, Jarabo JR, Calatayud J, Torres-Garcia
AJ and Iniesta P: Telomere length and telomerase activity in
non-small cell lung cancer prognosis: Clinical usefulness of a
specific telomere status. J Exp Clin Cancer Res. 34:782015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hara H, Yamashita K, Shinada J, Yoshimura
H and Kameya T: Clinicopathologic significance of telomerase
activity and hTERT mRNA expression in non-small cell lung cancer.
Lung Cancer. 34:219–226. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hashim M, Sayed M, Samy N and Elshazly S:
Prognostic significance of telomerase activity and some tumor
markers in non-small cell lung cancer. Med Oncol. 28:322–330. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Taga S, Osaki T, Ohgami A, Imoto H and
Yasumoto K: Prognostic impact of telomerase activity in non-small
cell lung cancers. Ann Surg. 230:715–720. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu TC, Lin P, Hsu CP, Huang YJ, Chen CY,
Chung WC, Lee H and Ko JL: Loss of telomerase activity may be a
potential favorable prognostic marker in lung carcinomas. Lung
Cancer. 41:163–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu CP, Miaw J, Hsia JY, Shai SE and Chen
CY: Concordant expression of the telomerase-associated genes in
non-small cell lung cancer. Eur J Surg Oncol. 29:594–599. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen KY, Lee LN, Yu CJ, Lee YC, Kuo SH and
Yang PC: Elevation of telomerase activity positively correlates to
poor prognosis of patients with non-small cell lung cancer. Cancer
Lett. 240:148–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Metzger R, Vallbohmer D, Muller-Tidow C,
Higashi H, Bollschweiler E, Warnecke-Eberz U, Brabender J, Baldus
SE, Xi H, Berdel WE, et al: Increased human telomerase reverse
transcriptase (hTERT) mRNA expression but not telomerase activity
is related to survival in curatively resected non-small cell lung
cancer. Anticancer Res. 29:1157–1162. 2009.PubMed/NCBI
|
|
43
|
Li L, Xiong YY, Liu L, Chen TX, Yao XF and
Wang YW: Relationships among expressions of hTERT, MDR1, MRP mRNA,
and C-myc protein in non-small cell lung cancer. Ai Zheng.
24:53–57. 2005.(In Chinese). PubMed/NCBI
|
|
44
|
Ding M, Li X and Qiu T: Combination of
multiple gene markers to detect circulating tumor cells in the
peripheral blood of patients with non-small cell lung cancer using
real-time PCR. Genet Mol Res. 14:13033–13040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zalewska-Ziob M, Dobija-Kubica K,
Biernacki K, Adamek B, Kasperczyk J, Brulinski K and Ostrowska Z:
Clinical and prognostic value of hTERT mRNA expression in patients
with non-small-cell lung cancer. Acta Biochim Pol. 64:641–646.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang J, Liu X and Fang J: Expression and
clinical significance of telomerase catalytic subunit gene in lung
cancer and its correlations with genes related to drug resistance
and apoptosis. Zhonghua Zhong Liu Za Zhi. 21:350–353. 1999.(In
Chinese). PubMed/NCBI
|
|
47
|
Cong YS, Wen J and Bacchetti S: The human
telomerase catalytic subunit hTERT: Organization of the gene and
characterization of the promoter. Hum Mol Genet. 8:137–142. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heidenreich B and Kumar R: TERT promoter
mutations in telomere biology. Mutat Res. 771:15–31. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Stern JL, Theodorescu D, Vogelstein B,
Papadopoulos N and Cech TR: Mutation of the TERT promoter, switch
to active chromatin, and monoallelic TERT expression in multiple
cancers. Genes Dev. 29:2219–2224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Akincilar SC, Unal B and Tergaonkar V:
Reactivation of telomerase in cancer. Cell Mol Life Sci.
73:1659–1670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Heidenreich B, Rachakonda PS, Hemminki K
and Kumar R: TERT promoter mutations in cancer development. Curr
Opin Genet Dev. 24:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vinagre J, Almeida A, Populo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hsu CP, Hsu NY, Lee LW and Ko JL: Ets2
binding site single nucleotide polymorphism at the hTERT gene
promoter-effect on telomerase expression and telomere length
maintenance in non-small cell lung cancer. Eur J Cancer.
42:1466–1474. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ma X, Gong R, Wang R, Pan Y, Cai D, Pan B,
Li Y, Xiang J, Li H, Zhang J, et al: Recurrent TERT promoter
mutations in non-small cell lung cancers. Lung Cancer. 86:369–373.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Griewank KG, Murali R, Schilling B,
Schimming T, Moller I, Moll I, Schwamborn M, Sucker A, Zimmer L,
Schadendorf D and Hillen U: TERT promoter mutations are frequent in
cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS
One. 8:e803542013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yuan P, Cao JL, Abuduwufuer A, Wang LM,
Yuan XS, Lv W and Hu J: Clinical characteristics and prognostic
significance of TERT promoter mutations in cancer: A cohort study
and a meta-analysis. PLoS One. 11:e01468032016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li C, Hao L, Li Y, Wang S, Chen H, Zhang
L, Ke B, Yin Y, Suo H, Sun B, et al: Prognostic value analysis of
mutational and clinicopathological factors in non-small cell lung
cancer. PLoS One. 9:e1072762014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schwaederle M, Krishnamurthy N, Daniels
GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA
and Kurzrock R: Telomerase reverse transcriptase promoter
alterations across cancer types as detected by next-generation
sequencing: A clinical and molecular analysis of 423 patients.
Cancer. 124:1288–1296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cheng KA, Kurtis B, Babayeva S, Zhuge J,
Tantchou I, Cai D, Lafaro RJ, Fallon JT and Zhong M: Heterogeneity
of TERT promoter mutations status in squamous cell carcinomas of
different anatomical sites. Ann Diagn Pathol. 19:146–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Feuk L, Carson AR and Scherer SW:
Structural variation in the human genome. Nat Rev Genet. 7:85–97.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yuan P, Huang S, Bao FC, Cao JL, Sheng HX,
Shi L, Lv W and Hu J: Discriminating association of a common
telomerase reverse transcriptase promoter polymorphism with
telomere parameters in non-small cell lung cancer with or without
epidermal growth factor receptor mutation. Eur J Cancer. 120:10–19.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lewis KA and Tollefsbol TO: Regulation of
the telomerase reverse transcriptase subunit through epigenetic
mechanisms. Front Genet. 7:832016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sarne V, Huter S, Braunmueller S, Rakob L,
Jacobi N, Kitzwogerer M, Wiesner C, Obrist P and Seeboeck R:
Promoter methylation of selected genes in non-small-cell lung
cancer patients and cell lines. Int J Mol Sci. 21:45952020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Guilleret I, Yan P, Grange F, Braunschweig
R, Bosman FT and Benhattar J: Hypermethylation of the human
telomerase catalytic subunit (hTERT) gene correlates with
telomerase activity. Int J Cancer. 101:335–341. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Devereux TR, Horikawa I, Anna CH, Annab
LA, Afshari CA and Barrett JC: DNA methylation analysis of the
promoter region of the human telomerase reverse transcriptase
(hTERT) gene. Cancer Res. 59:6087–6090. 1999.PubMed/NCBI
|
|
68
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mamdani H and Jalal SI: Histone
Deacetylase inhibition in non-small cell lung cancer: Hype or Hope?
Front Cell Dev Biol. 8:5823702020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wu YF, Ou CC, Chien PJ, Chang HY, Ko JL
and Wang BY: Chidamide-induced ROS accumulation and
miR-129-3p-dependent cell cycle arrest in non-small lung cancer
cells. Phytomedicine. 56:94–102. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li CT, Hsiao YM, Wu TC, Lin YW, Yeh KT and
Ko JL: Vorinostat, SAHA, represses telomerase activity via
epigenetic regulation of telomerase reverse transcriptase in
non-small cell lung cancer cells. J Cell Biochem. 112:3044–3053.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Krupitsky EM, Rybakova KV, Skurat EP,
Semenova NV and Neznanov NG: A double blind placebo controlled
randomized clinical trial of the efficacy and safety of pregabalin
in induction of remission in patients with alcohol dependence. Zh
Nevrol Psikhiatr Im S S Korsakova. 120:33–43. 2020.(In Russian).
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd
FA, Squire JA and Tsao MS: Amplification of telomerase (hTERT) gene
is a poor prognostic marker in non-small-cell lung cancer. Br J
Cancer. 94:1452–1459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang A, Zheng C, Lindvall C, Hou M,
Ekedahl J, Lewensohn R, Yan Z, Yang X, Henriksson M, Blennow E, et
al: Frequent amplification of the telomerase reverse transcriptase
gene in human tumors. Cancer Res. 60:6230–6235. 2000.PubMed/NCBI
|
|
75
|
Takuma Y, Nouso K, Kobayashi Y, Nakamura
S, Tanaka H, Matsumoto E, Fujikawa T, Suzuki M, Hanafusa T and
Shiratori Y: Telomerase reverse transcriptase gene amplification in
hepatocellular carcinoma. J Gastroenterol Hepatol. 19:1300–1304.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang A, Zheng C, Hou M, Lindvall C,
Wallin KL, Angstrom T, Yang X, Hellstrom AC, Blennow E, Bjorkholm
M, et al: Amplification of the telomerase reverse transcriptase
(hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer.
34:269–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tsuda H, Akiyama F, Terasaki H, Hasegawa
T, Kurosumi M, Shimadzu M, Yamamori S and Sakamoto G: Detection of
HER-2/neu (c-erb B-2) DNA amplification in primary breast
carcinoma. Interobserver reproducibility and correlation with
immunohistochemical HER-2 overexpression. Cancer. 92:2965–2974.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kang JU, Koo SH, Kwon KC, Park JW and Kim
JM: Gain at chromosomal region 5p15.33, containing TERT, is the
most frequent genetic event in early stages of non-small cell lung
cancer. Cancer Genet Cytogenet. 182:1–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Alidousty C, Baar T, Martelotto LG, Heydt
C, Wagener S, Fassunke J, Duerbaum N, Scheel AH, Frank S, Holz B,
et al: Genetic instability and recurrent MYC amplification in
ALK-translocated NSCLC: A central role of TP53 mutations. J Pathol.
246:67–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Peifer M, Hertwig F, Roels F, Dreidax D,
Gartlgruber M, Menon R, Kramer A, Roncaioli JL, Sand F, Heuckmann
JM, et al: Telomerase activation by genomic rearrangements in
high-risk neuroblastoma. Nature. 526:700–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bayard Q, Meunier L, Peneau C, Renault V,
Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, et al:
Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass
with a rearrangement signature of replication stress. Nat Commun.
9:52352018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kawashima M, Kojima M, Ueda Y, Kurihara S
and Hiyama E: Telomere biology including TERT rearrangements in
neuroblastoma: A useful indicator for surgical treatments. J
Pediatr Surg. 51:2080–2085. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Mender I, LaRanger R, Luitel K, Peyton M,
Girard L, Lai TP, Batten K, Cornelius C, Dalvi MP, Ramirez M, et
al: Telomerase-mediated strategy for overcoming non-small cell lung
cancer targeted therapy and chemotherapy resistance. Neoplasia.
20:826–837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ward RJ and Autexier C: Pharmacological
telomerase inhibition can sensitize drug-resistant and
drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol.
68:779–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Meng E, Taylor B, Ray A, Shevde LA and
Rocconi RP: Targeted inhibition of telomerase activity combined
with chemotherapy demonstrates synergy in eliminating ovarian
cancer spheroid-forming cells. Gynecol Oncol. 124:598–605. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhang G, Wu LW, Mender I, Barzily-Rokni M,
Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, et
al: Induction of telomere dysfunction prolongs disease control of
therapy-resistant melanoma. Clin Cancer Res. 24:4771–4784. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Dikmen ZG, Gellert GC, Jackson S, Gryaznov
S, Tressler R, Dogan P, Wright WE and Shay JW: In vivo inhibition
of lung cancer by GRN163L: A novel human telomerase inhibitor.
Cancer Res. 65:7866–7873. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mender I, Gryaznov S, Dikmen ZG, Wright WE
and Shay JW: Induction of telomere dysfunction mediated by the
telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer
Discov. 5:82–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pascolo E, Wenz C, Lingner J, Hauel N,
Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K and
Schnapp A: Mechanism of human telomerase inhibition by BIBR1532, a
synthetic, non-nucleosidic drug candidate. J Biol Chem.
277:15566–15572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian
D, Li C, Zhang H, Wang S, Zhu J, et al: Kras mutations increase
telomerase activity and targeting telomerase is a promising
therapeutic strategy for Kras-mutant NSCLC. Oncotarget. 8:179–190.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ding X, Cheng J, Pang Q, Wei X, Zhang X,
Wang P, Yuan Z and Qian D: BIBR1532, a selective telomerase
inhibitor, enhances radiosensitivity of non-small cell lung cancer
through increasing telomere dysfunction and ATM/CHK1 inhibition.
Int J Radiat Oncol Biol Phys. 105:861–874. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Webb D, Gagnon MM and Rose T: Metabolic
enzyme activities in black bream (Acanthopagrus butcheri)
from the Swan-Canning Estuary, Western Australia. Comp Biochem
Physiol C Toxicol Pharmacol. 141:356–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Gellert GC, Dikmen ZG, Wright WE, Gryaznov
S and Shay JW: Effects of a novel telomerase inhibitor, GRN163L, in
human breast cancer. Breast Cancer Res Treat. 96:73–81. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Frink RE, Peyton M, Schiller JH, Gazdar
AF, Shay JW and Minna JD: Telomerase inhibitor imetelstat has
preclinical activity across the spectrum of non-small cell lung
cancer oncogenotypes in a telomere length dependent manner.
Oncotarget. 7:31639–31651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Herbert BS, Gellert GC, Hochreiter A,
Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW and
Gryaznov SM: Lipid modification of GRN163, an N3′-->P5′
thio-phosphoramidate oligonucleotide, enhances the potency of
telomerase inhibition. Oncogene. 24:5262–5268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mender I, Senturk S, Ozgunes N, Akcali KC,
Kletsas D, Gryaznov S, Can A, Shay JW and Dikmen ZG: Imetelstat (a
telomerase antagonist) exerts offtarget effects on the
cytoskeleton. Int J Oncol. 42:1709–1715. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chiappori AA, Kolevska T, Spigel DR, Hager
S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, et
al: A randomized phase II study of the telomerase inhibitor
imetelstat as maintenance therapy for advanced non-small-cell lung
cancer. Ann Oncol. 26:354–362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Negrini S, De Palma R and Filaci G:
Anti-cancer immunotherapies targeting telomerase. Cancers (Basel).
12:22602020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Brunsvig PF, Kyte JA, Kersten C, Sundstrom
S, Moller M, Nyakas M, Hansen GL, Gaudernack G and Aamdal S:
Telomerase peptide vaccination in NSCLC: A phase II trial in stage
III patients vaccinated after chemoradiotherapy and an 8-year
update on a phase I/II trial. Clin Cancer Res. 17:6847–6857. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Relitti N, Saraswati AP, Federico S, Khan
T, Brindisi M, Zisterer D, Brogi S, Gemma S, Butini S and Campiani
G: Telomerase-based cancer therapeutics: A review on their clinical
trials. Curr Top Med Chem. 20:433–457. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Brunsvig PF, Aamdal S, Gjertsen MK,
Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S,
Moller M, Eriksen JA, et al: Telomerase peptide vaccination: A
phase I/II study in patients with non-small cell lung cancer.
Cancer Immunol Immunother. 55:1553–1564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hansen GL, Gaudernack G, Brunsvig PF,
Cvancarova M and Kyte JA: Immunological factors influencing
clinical outcome in lung cancer patients after telomerase peptide
vaccination. Cancer Immunol Immunother. 64:1609–1621. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Vetsika EK, Konsolakis G, Aggouraki D,
Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J,
Kosmatopoulos K, Georgoulias V and Mavroudis D: Immunological
responses in cancer patients after vaccination with the therapeutic
telomerase-specific vaccine Vx-001. Cancer Immunol Immunother.
61:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kotsakis A, Papadimitraki E, Vetsika EK,
Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis
D and Georgoulias V: A phase II trial evaluating the clinical and
immunologic response of HLA-A2(+) non-small cell lung cancer
patients vaccinated with an hTERT cryptic peptide. Lung Cancer.
86:59–66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Bolonaki I, Kotsakis A, Papadimitraki E,
Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I,
Magganas E, Galanis A, et al: Vaccination of patients with advanced
non-small-cell lung cancer with an optimized cryptic human
telomerase reverse transcriptase peptide. J Clin Oncol.
25:2727–2734. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gridelli C, Ciuleanu T, Domine M, Szczesna
A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C,
Kazarnowisz A, et al: Clinical activity of a htert (vx-001) cancer
vaccine as post-chemotherapy maintenance immunotherapy in patients
with stage IV non-small cell lung cancer: Final results of a
randomised phase 2 clinical trial. Br J Cancer. 122:1461–1466.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Yuan X, Larsson C and Xu D: Mechanisms
underlying the activation of TERT transcription and telomerase
activity in human cancer: Old actors and new players. Oncogene.
38:6172–6183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lantuejoul S, Soria JC, Moro-Sibilot D,
Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C
and Brambilla E: Differential expression of telomerase reverse
transcriptase (hTERT) in lung tumours. Br J Cancer. 90:1222–1229.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Marchetti A, Bertacca G, Buttitta F,
Chella A, Quattrocolo G, Angeletti CA and Bevilacqua G: Telomerase
activity as a prognostic indicator in stage I non-small cell lung
cancer. Clin Cancer Res. 5:2077–2081. 1999.PubMed/NCBI
|
|
110
|
Tang H, Wang H, Cheng X, Fan X, Yang F,
Zhang M, Chen Y, Tian Y, Liu C, Shao D, et al: HuR regulates
telomerase activity through TERC methylation. Nat Commun.
9:22132018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Baena-Del Valle JA, Zheng Q, Esopi DM,
Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A,
Yegnasubramanian S, Wheelan SJ, et al: MYC drives overexpression of
telomerase RNA (hTR/TERC) in prostate cancer. J Pathol. 244:11–24.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Bellutti F, Tigan AS, Nebenfuehr S,
Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S,
Doma E, Prchal-Murphy M, et al: CDK6 antagonizes p53-induced
responses during tumorigenesis. Cancer Discov. 8:884–897. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wu XQ, Huang C, He X, Tian YY, Zhou DX, He
Y, Liu XH and Li J: Feedback regulation of telomerase reverse
transcriptase: New insight into the evolving field of telomerase in
cancer. Cell Signal. 25:2462–2468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chen W, Lu J, Qin Y, Wang J, Tian Y, Shi
D, Wang S, Xiao Y, Dai M, Liu L, et al: Ret finger protein-like 3
promotes tumor cell growth by activating telomerase reverse
transcriptase expression in human lung cancer cells. Oncotarget.
5:11909–11923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Lin C, Qin Y, Zhang H, Gao MY and Wang YF:
EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in
nonsmall cell lung cancer cells. Oncol Rep. 40:29–38.
2018.PubMed/NCBI
|
|
116
|
Guo W, Lu J, Dai M, Wu T, Yu Z, Wang J,
Chen W, Shi D, Yu W, Xiao Y, et al: Transcriptional coactivator CBP
upregulates hTERT expression and tumor growth and predicts poor
prognosis in human lung cancers. Oncotarget. 5:9349–9361. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang F, Fu P, Pang Y, Liu C, Shao Z, Zhu
J, Li J, Wang T, Zhang X and Liu J: TERT rs2736100T/G polymorphism
upregulates interleukin 6 expression in non-small cell lung cancer
especially in adenocarcinoma. Tumour Biol. 35:4667–4672. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Maniwa Y, Yoshimura M, Obayashi C, Inaba
M, Kiyooka K, Kanki M and Okita Y: Association of p53 gene mutation
and telomerase activity in resectable non-small cell lung cancer.
Chest. 120:589–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kiyooka K, Maniwa Y and Okada M: Analysis
of mutant p53 and telomerase activity in non-small cell lung
cancer. Ann Thorac Cardiovasc Surg. 5:293–299. 1999.PubMed/NCBI
|
